WithdrawnInterventionalPhase 2Phase 3Last updated Jul 30, 2015

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)

Overview

ClinicalTrials.gov ID: NCT01609452
Lead Sponsor: Anthera PharmaceuticalsINDUSTRY
Brief Summary: The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when administered on top of standard-of-care to subjects with Immune Thrombocytopenic Purpura (ITP).
Study Type: Interventional

Status

Overall Status: Withdrawn
Start Date: Dec 2015
Primary Completion Date: Jun 2016Estimated
Completion Date: No data available

Study Record Dates

First Submitted: May 23, 2012
First Submitted that Met QC Criteria: May 29, 2012
First Posted: Jun 1, 2012Estimated
Last Update Submitted that Met QC Criteria: Jul 28, 2015
Last Update Posted: Jul 30, 2015Estimated
Last Verified: Jul 2015

NCT00102739Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

NCT00540423Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00102323Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

NCT02273960Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

NCT03275454Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

NCT05653349Active, not recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)